Randomized controlled trial of adjuvant chemotherapy with fluoropyrimidines versus surgery-alone for gastric cancer

Jeong Ho Moon, Yoshiyuki Fujiwara, Motohiro Hirao, Hiroshi Imamura, Yutaka Kimura, Kazumasa Fujitani, Junya Fujita, Shigeyuki Tamura, Shuji Takiguchi, Masahiko Yano, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: This prospective randomized study compared the survival of patients with stage IB-IIIA gastric cancer treated with surgery alone or surgery followed by adjuvant chemotherapy. Patients and Methods: Patients with pathological stage IB-IIIA disease were randomly assigned to the following groups: surgery alone (n=116), or surgery followed by adjuvant chemotherapy with 5-fluorouracil, doxifluridine, or uracil-tegafur for 12 months (n=113). Results: The overall survival rate was 86.1% in the adjuvant group and 78.5% in the surgery-alone group. The overall survival rate did not significantly differ between the adjuvant-chemotherapy and surgery-only groups (p=0.163). In the subgroup analyses, patients with stage II disease and those receiving uracil-tegafur treatment in the adjuvant group showed significantly better prognosis than those in the surgery-alone group (p=0.036 and 0.005, respectively). Conclusion: This study did not find a significant survival benefit to be associated with adjuvant chemotherapy with fluoropyrimidines in patients with stage IBIIIA gastric cancer. However, it may be effective for patients with stage II disease. Additionally, uracil-tegafur is a promising agent for adjuvant chemotherapy of gastric cancer if S-1 is not available because of its toxicity.

Original languageEnglish
Pages (from-to)3061-3067
Number of pages7
JournalAnticancer research
Volume37
Issue number6
DOIs
Publication statusPublished - Jun 1 2017
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Stomach Neoplasms
Randomized Controlled Trials
Tegafur
Uracil
Survival Rate
Survival
Fluorouracil
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Moon, J. H., Fujiwara, Y., Hirao, M., Imamura, H., Kimura, Y., Fujitani, K., ... Doki, Y. (2017). Randomized controlled trial of adjuvant chemotherapy with fluoropyrimidines versus surgery-alone for gastric cancer. Anticancer research, 37(6), 3061-3067. https://doi.org/10.21873/anticanres.11661

Randomized controlled trial of adjuvant chemotherapy with fluoropyrimidines versus surgery-alone for gastric cancer. / Moon, Jeong Ho; Fujiwara, Yoshiyuki; Hirao, Motohiro; Imamura, Hiroshi; Kimura, Yutaka; Fujitani, Kazumasa; Fujita, Junya; Tamura, Shigeyuki; Takiguchi, Shuji; Yano, Masahiko; Mori, Masaki; Doki, Yuichiro.

In: Anticancer research, Vol. 37, No. 6, 01.06.2017, p. 3061-3067.

Research output: Contribution to journalArticle

Moon, JH, Fujiwara, Y, Hirao, M, Imamura, H, Kimura, Y, Fujitani, K, Fujita, J, Tamura, S, Takiguchi, S, Yano, M, Mori, M & Doki, Y 2017, 'Randomized controlled trial of adjuvant chemotherapy with fluoropyrimidines versus surgery-alone for gastric cancer', Anticancer research, vol. 37, no. 6, pp. 3061-3067. https://doi.org/10.21873/anticanres.11661
Moon, Jeong Ho ; Fujiwara, Yoshiyuki ; Hirao, Motohiro ; Imamura, Hiroshi ; Kimura, Yutaka ; Fujitani, Kazumasa ; Fujita, Junya ; Tamura, Shigeyuki ; Takiguchi, Shuji ; Yano, Masahiko ; Mori, Masaki ; Doki, Yuichiro. / Randomized controlled trial of adjuvant chemotherapy with fluoropyrimidines versus surgery-alone for gastric cancer. In: Anticancer research. 2017 ; Vol. 37, No. 6. pp. 3061-3067.
@article{38ef10013d954620aa3609586138158a,
title = "Randomized controlled trial of adjuvant chemotherapy with fluoropyrimidines versus surgery-alone for gastric cancer",
abstract = "Aim: This prospective randomized study compared the survival of patients with stage IB-IIIA gastric cancer treated with surgery alone or surgery followed by adjuvant chemotherapy. Patients and Methods: Patients with pathological stage IB-IIIA disease were randomly assigned to the following groups: surgery alone (n=116), or surgery followed by adjuvant chemotherapy with 5-fluorouracil, doxifluridine, or uracil-tegafur for 12 months (n=113). Results: The overall survival rate was 86.1{\%} in the adjuvant group and 78.5{\%} in the surgery-alone group. The overall survival rate did not significantly differ between the adjuvant-chemotherapy and surgery-only groups (p=0.163). In the subgroup analyses, patients with stage II disease and those receiving uracil-tegafur treatment in the adjuvant group showed significantly better prognosis than those in the surgery-alone group (p=0.036 and 0.005, respectively). Conclusion: This study did not find a significant survival benefit to be associated with adjuvant chemotherapy with fluoropyrimidines in patients with stage IBIIIA gastric cancer. However, it may be effective for patients with stage II disease. Additionally, uracil-tegafur is a promising agent for adjuvant chemotherapy of gastric cancer if S-1 is not available because of its toxicity.",
author = "Moon, {Jeong Ho} and Yoshiyuki Fujiwara and Motohiro Hirao and Hiroshi Imamura and Yutaka Kimura and Kazumasa Fujitani and Junya Fujita and Shigeyuki Tamura and Shuji Takiguchi and Masahiko Yano and Masaki Mori and Yuichiro Doki",
year = "2017",
month = "6",
day = "1",
doi = "10.21873/anticanres.11661",
language = "English",
volume = "37",
pages = "3061--3067",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Randomized controlled trial of adjuvant chemotherapy with fluoropyrimidines versus surgery-alone for gastric cancer

AU - Moon, Jeong Ho

AU - Fujiwara, Yoshiyuki

AU - Hirao, Motohiro

AU - Imamura, Hiroshi

AU - Kimura, Yutaka

AU - Fujitani, Kazumasa

AU - Fujita, Junya

AU - Tamura, Shigeyuki

AU - Takiguchi, Shuji

AU - Yano, Masahiko

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Aim: This prospective randomized study compared the survival of patients with stage IB-IIIA gastric cancer treated with surgery alone or surgery followed by adjuvant chemotherapy. Patients and Methods: Patients with pathological stage IB-IIIA disease were randomly assigned to the following groups: surgery alone (n=116), or surgery followed by adjuvant chemotherapy with 5-fluorouracil, doxifluridine, or uracil-tegafur for 12 months (n=113). Results: The overall survival rate was 86.1% in the adjuvant group and 78.5% in the surgery-alone group. The overall survival rate did not significantly differ between the adjuvant-chemotherapy and surgery-only groups (p=0.163). In the subgroup analyses, patients with stage II disease and those receiving uracil-tegafur treatment in the adjuvant group showed significantly better prognosis than those in the surgery-alone group (p=0.036 and 0.005, respectively). Conclusion: This study did not find a significant survival benefit to be associated with adjuvant chemotherapy with fluoropyrimidines in patients with stage IBIIIA gastric cancer. However, it may be effective for patients with stage II disease. Additionally, uracil-tegafur is a promising agent for adjuvant chemotherapy of gastric cancer if S-1 is not available because of its toxicity.

AB - Aim: This prospective randomized study compared the survival of patients with stage IB-IIIA gastric cancer treated with surgery alone or surgery followed by adjuvant chemotherapy. Patients and Methods: Patients with pathological stage IB-IIIA disease were randomly assigned to the following groups: surgery alone (n=116), or surgery followed by adjuvant chemotherapy with 5-fluorouracil, doxifluridine, or uracil-tegafur for 12 months (n=113). Results: The overall survival rate was 86.1% in the adjuvant group and 78.5% in the surgery-alone group. The overall survival rate did not significantly differ between the adjuvant-chemotherapy and surgery-only groups (p=0.163). In the subgroup analyses, patients with stage II disease and those receiving uracil-tegafur treatment in the adjuvant group showed significantly better prognosis than those in the surgery-alone group (p=0.036 and 0.005, respectively). Conclusion: This study did not find a significant survival benefit to be associated with adjuvant chemotherapy with fluoropyrimidines in patients with stage IBIIIA gastric cancer. However, it may be effective for patients with stage II disease. Additionally, uracil-tegafur is a promising agent for adjuvant chemotherapy of gastric cancer if S-1 is not available because of its toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85019760616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019760616&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11661

DO - 10.21873/anticanres.11661

M3 - Article

C2 - 28551645

AN - SCOPUS:85019760616

VL - 37

SP - 3061

EP - 3067

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -